Melanoma May Have A Natural Enemy: A Tiny Protein Fragment The Human Body Already Produces

Skin cancer kills more Americans than most people realize. Melanoma, the deadliest form of skin cancer, accounts for more than 80% of skin cancer deaths despite making up a small fraction of all cases. What makes it especially dangerous is its ability to spread fast and stop responding to the drugs designed to fight it. Now, scientists have identified an unexpected ally: a tiny protein fragment the human body already makes, one that slowed melanoma tumor growth in mice while also showing activity against a lab model of one of the disease’s most stubborn traits, drug resistance.

That fragment is called catestatin, a small piece of a larger protein called Chromogranin A, produced in hormone-secreting tissues throughout the body. Researchers already knew catestatin could reduce inflammation, regulate blood pressure, and help manage blood sugar. A study published in the journal Oncogenesis now reports, for the first time, evidence that it can also slow melanoma growth, trigger cancer cell death, and show activity against cells engineered in the lab to resist a targeted melanoma drug.

Crucially, catestatin levels appear to drop sharply as melanoma advances. Analysis of human tissue samples showed that normal skin and early-stage tumors still had plenty of the protein fragment, while later-stage and metastatic samples had far less. The study does not prove that the decline alone causes tumor progression, but the pattern raises questions worth investigating.

Catestatin Targeted Melanoma Cells While Sparing Healthy Tissue

Researchers at the University of California, San Diego and affiliated institutions tested catestatin across several fronts: human melanoma tissue, patient-derived cancer cell lines from the National Cancer Institute’s tumor repository, established laboratory cell lines, and mice carrying melanoma tumors.

In lab dishes, melanoma cells died in increasing numbers the more catestatin they were exposed to. Normal human skin cells were unaffected even at the highest concentrations tested, pointing to what the researchers call tumor-selective activity. Beyond cell death, catestatin sharply cut the ability of melanoma cells to form new colonies and to migrate, two behaviors central to how the cancer spreads through the body.

Moving the tests into living animals, researchers injected melanoma cells under the skin of mice and administered catestatin three times per week. Compared to untreated controls, those receiving catestatin showed significantly reduced tumor growth and lower tumor weight. No major changes in body weight or liver tissue were observed, indicating the treatment did not appear to cause detectable harm to the rest of the body.

To understand the mechanism behind these results, the team analyzed the activity of thousands of genes in both the mouse tumors and human melanoma cell lines. Catestatin dialed down biological programs that melanoma typically uses to survive and spread, including processes that help cancer cells move through surrounding tissue and adapt to low-oxygen environments common in fast-growing tumors. Four proteins, CCN2, LOXL2, DDIT4, and PDGFRB, were significantly reduced after catestatin treatment in both models. All four have previously been linked to melanoma aggression, and data from a large public cancer genomics database confirmed their levels tend to be elevated in patients with more advanced disease.

Catestatin Showed Activity Against Drug-Resistant Melanoma Cells in Lab Tests

Perhaps the most attention-grabbing part of the study involves Vemurafenib, a targeted drug used for melanomas carrying a BRAF V600E mutation, a specific genetic change found in a significant proportion of melanoma patients. It has transformed outcomes for many patients, but resistance is a persistent problem that leaves some people with few remaining options.

Researchers created a Vemurafenib-resistant melanoma cell line in the laboratory by gradually exposing cells to increasing amounts of the drug over several weeks until the surviving cells were highly resistant. Those resistant cells required much higher drug exposure than non-resistant cells to achieve the same effect. When catestatin was applied to them, it still markedly reduced their ability to survive and migrate. Vemurafenib alone had little effect on the resistant cells, while catestatin alone, and catestatin combined with Vemurafenib, led to a substantial drop in cell survival. Genetic analysis after treatment revealed that a suite of genes known to drive drug resistance had been switched off. One patient-derived line used in the study came from a patient who had not responded to Vemurafenib, and that line showed heightened sensitivity to catestatin.

Catestatin has not been tested as a melanoma treatment in people, and these are early-stage preclinical findings, so patients should not change their care plans based on this research. What the study does establish is that a naturally occurring fragment of a human protein can interfere with biological programs that make melanoma so hard to kill, and do so without apparent harm to healthy tissue in lab and mouse tests, giving researchers a direction worth pursuing.

---

Disclaimer: This article is based on early-stage preclinical research and is intended for informational purposes only. It does not constitute medical advice. Catestatin has not been tested as a melanoma treatment in people. Always consult a qualified healthcare provider before making any medical decisions.

---